 The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and anti-inflammatory effects of a single intratracheal IT dose of rhCC10 to intubated premature infants receiving positive pressure ventilation for treatment of respiratory distress syndrome RDS to prevent long term respiratory complications referred to as bronchopulmonary dysplasia, and, more recently, as chronic respiratory morbidity CRM; asthma, cough, wheezing, multiple respiratory infections. 